What one share of CapsoVision holds
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care.
CapsoVision’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$0.63 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.59 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $5.82 | −$9.85 | $0.08 | −$10.02 | — | −$61.94 |
| 2025 | $0.55 | −$1.03 | $0.00 | −$0.93 | — | $0.28 |
Common questions about CapsoVision
How much does one share of CapsoVision earn?
Over the last 12 months, CapsoVision lost $0.63 for each share on $0.29 of sales.
Does CapsoVision pay a dividend?
CapsoVision didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CapsoVision’s book value per share?
CapsoVision’s book value is $0.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
What is CapsoVision’s free cash flow per share?
−$0.59 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.